Accept Cookies

Cookies: We use cookies on our website to make it clear, useful and reliable. This includes storing a small amount of data about you. By navigating to other sections of our website, you are consenting to information being stored. Find out more here.

Coronavirus: Stay alert, protect the NHS, save lives... Find our Covid-19 information and updates here >
National services

Our experts

National services

Our experts

National services

Our experts

National services

Our experts

Dr James Rucker

Honorary Consultant Psychiatrist



Biography 

Dr James Rucker is an Honorary Consultant Psychiatrist and NIHR Clinician Scientist Fellow, specialising in mood disorders and psychopharmacology, at the Centre for Affective Disorders at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London (UK). Dr Rucker completed his medical degree at University College London (UK) in 2003 before training in psychiatry at the Maudsley, Bethlem and Springfield Hospitals in South London. He completed his PhD in the molecular biology of mood disorders at King’s College London in 2012.

Dr Rucker specialises in novel treatments in mood, anxiety and trauma response disorders and is particularly interested in the therapeutic interface of psychotherapy, psychopharmacology and society. He leads The Psychedelic Trials Group at King’s College London, which undertake gold standard clinical trials of psilocybin and MDMA assisted therapy for treatment resistant mood, anxiety and post-traumatic stress disorders. He is also one of the few psychiatrists in the UK trained to prescribe medical cannabis in the treatment of psychiatric conditions.


Current Employment

2018-present NIHR Clinician Scientist Fellow. The Institute of Psychiatry, Psychology and Neuroscience, Kings College London
2018-present Honorary Consultant Psychiatrist. South London and Maudsley NHS Foundation Trust.
2014-present Honorary Clinical Research Fellow. The Centre for Neuropsychopharmacology, Imperial College London.
 

Degrees and Professional Qualifications

2020 Certificate in Clinical Trials. London School of Hygiene & Tropical Medicine
2018 Certificate of Completion of Training (CCT). General Adult & Old Psychiatry.
2012 Doctor of Philosophy (PhD), Kings College London, London, UK.
2007 Approval under Section 12(2) of the 1983 Mental Health Act
2007 MRCPsych, The Royal College of Psychiatrists, London, UK
2003 MBBS(Lond), University College London, London, UK
2000 BSc with 1st class honours in Medical Sciences and Human Physiology



Selected Publications

  1. Young, A. & Rucker, J. Historic Psychedelic Drug Trials And The Treatment Of Anxiety Disorders, 12 Jun 2020, (Accepted/In press) In : Depression and Anxiety. 16810959.
  2. Butler, M., Nicholson, T. R. J., Pick, S., Kanaan, R. A. A., Lees, A., Young, A. & Rucker, J. Psychedelic treatment of functional neurological disorder - a systematic review. 11 Feb 2020, (Accepted/In press) In : Therapeutic Advances in Psychopharmacology.
  3. Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. Writing Committee for the ENIGMA-CNV Working Group , 30 Oct 2019, In : JAMA Psychiatry. p. 1-11
  4. Zhang, X., Abdellaoui, A., Rucker, J., de Jong, S., Potash, J. B., Weissman, M. M., … Levinson, D. F. (2019). Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts. Biological Psychiatry, 0(0). https://doi.org/10.1016/j.biopsych.2019.02.022
  5. Rucker, J.J.H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. http://doi.org/10.1016/j.neuropharm.2017.12.040
  6. R. L. Carhart-Harris, M. Bolstridge, C. M. J. Day, J. Rucker, R. Watts, D. E. Erritzoe, M. Kaelen, B. Giribaldi, M. Bloomfield, S. Pilling, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, H. V. Curran, and D. J. Nutt, “Psilocybin with psychological support for treatment-resistant depression: six-month follow-up,” Psychopharmacology, vol. 29, no. 3, pp. 1–10, Nov. 2017. https://doi.org/10.1007/s00213-017-4771-x
  7. M. Rivera, A. E. Locke, T. Corre, D. Czamara, C. Wolf, A. Ching-Lopez, Y. Milaneschi, S. Kloiber, S. Cohen-Woods, J. Rucker, K. J. Aitchison, et al., “Interaction between the FTOgene, body mass index and depression: meta-analysis of 13701 individuals,” The British Journal of Psychiatry, vol. 211, no. 2, pp. 70–76, Aug. 2017. https://dx.doi.org/10.1192%2Fbjp.bp.116.183475
  8. Rucker, J & Winstock, A (2017). Psychedelics. In: The Oxford Textbook of Psychiatry (2017)(in press)
  9. Rucker, J.J., Jelen, L., Flynn, S., Frowde, K & Young, A (2016). Psychedelics in the Treatment of Unipolar Mood Disorders: A Systematic Review. Journal of Psychopharmacology (Oxford, England), 0269881116679368. http://doi.org/10.1177/0269881116679368
  10. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet, 3(7), 619–627. http://doi.org/10.1016/S2215-0366(16)30065-7
  11. Rucker JJH, Tansey KE, Rivera M, Pinto D, Cohen-Woods S, et al. (2015) Phenotypic Association Analyses with Copy Number Variation in Recurrent Depressive Disorder. Biol Psychiatry, 79(4): 329–336. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725574/
  12. Rucker JJ, McGuffin P (2014) Chipping away at major depressive disorder. Genome Biol 15: 421. doi:10.1186/s13059-014-0421-3.
  13. Rucker JJH & McGuffin P. Genomic structural variation in psychiatric disorders. Development and Psychopathology (2012). 24;4;1335-1344. doi:10.1017/S0954579412000740
  14. Rucker J. Affective Psychopharmacology Prescribing, in Nicholson TR*, Gunarathne A, Singer DR (Eds.). Pocket Prescriber 2012. 5th Edition. Hodder Arnold, London 2012. Expert contributor to affective psychopharmacology section. ISBN-10: 1444163167
  15. Rucker JJH, Breen G, Pinto D, Pedroso I, Lewis, CM, et al. Genome-wide association analysis of copy number variation in recurrent depressive disorder. Molecular Psychiatry 18, 183-189 (2012), doi:10.1038/mp.2011.144
  16. Rucker JJH, Newman S, Gray J, Gunasinghe C et al. OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. British Journal of Psychiatry (2011). 199(2):151-5. doi:10.1192/bjp.bp.110.082925
  17. Rucker JJH, McGuffin P. Polygenic Heterogeneity: A Complex Model of Genetic Inheritance in Psychiatric Disorders. Biological Psychiatry (2010) 68;4;312-313. doi:10.1016/j.biopsych.2010.06.020
  18. Owen GS, Szmukler G, Richardson G, David AS, Hayward P, Rucker J, Harding D, Hotopf M, Mental capacity and psychiatric in-patients: implications for the new mental health law in England and Wales. 2009, Br J Psychiatry, 195, 257-63. doi:10.1192/bjp.bp.108.059782
  19. Rucker JJH, McGuffin P. Invited Editorial: Why do we need to understand the molecular basis of depression? Biomarkers in Medicine (2008) 2(2); 101-104.